Sunday, September 20, 2026

Canopy Growth Stock Went Down By Over 20% In The Last 10 Sessions

Canopy Growth Stock Went Down By Over 20% In The Last 10 Sessions

(VIANEWS) - Shares of Canopy Growth (NASDAQ: CGC) fell by a staggering 20.56% in 10 sessions from $1.07 at 2023-05-23, to $0.85 at 20:42 EST on Tuesday, after five successive sessions in a row of losses. NASDAQ is rising 0.32% to $13,017.43, after three successive sessions in a row of gains.

Canopy Growth's last close was $0.85, 87.55% below its 52-week high of $6.83.

About Canopy Growth

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-4.41.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -112%.

Yearly Top and Bottom Value

Canopy Growth's stock is valued at $0.85 at 20:42 EST, way under its 52-week low of $1.43.

Volatility

Canopy Growth's last week, last month's, and last quarter's current intraday variation average was a negative 9.78%, a negative 2.16%, and a positive 3.22%.

Canopy Growth's highest amplitude of average volatility was 9.78% (last week), 5.10% (last month), and 3.22% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth declined by 28.2%, now sitting on 440.96M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Canopy Growth's EBITDA is -12.41.

More news about Canopy Growth (CGC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com